tiprankstipranks
Blurbs

H.C. Wainwright Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on MoonLake Immunotherapeutics (MLTXResearch Report), with a price target of $28.00. The company’s shares opened today at $11.97.

Selvaraju covers the Healthcare sector, focusing on stocks such as Cocrystal Pharma, Enlivex, and ADMA Biologics. According to TipRanks, Selvaraju has an average return of -24.4% and a 27.63% success rate on recommended stocks.

Currently, the analyst consensus on MoonLake Immunotherapeutics is a Strong Buy with an average price target of $22.75.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $15.19 and a one-year low of $4.25. Currently, MoonLake Immunotherapeutics has an average volume of 78.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Helix Acquisition Corp is a blank check company.

Read More on MLTX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles